focus -WSS

focus

author：comprehensive 2025-09-30 16:14:53 - browse：4

Medicare and money photo illustration. — Adobe

Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier.

CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

“I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

entertainment

Wikipedia

WSS

Female surgeons have lower rates of long

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Medicare Advantage isn’t working — for anyone

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Readout Newsletter: Beam, Prozac, "TechBio" and more

Massive project maps cells in human brain in unprecedented detail

focus

focus

hotspot

Heart attack and stroke risk calculators need revising

CDC advisory group OKs chikungunya vaccine

Trump demands the U.S. pay no more for drugs than other countries … again

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Are embryos people? Reproductive medicine's future depends on the answer

Moonlake's readout produced a cash windfall. Risks remain

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

European regulators consider appeal over Amylyx ALS drug

hotspot

Children’s Hospital revives plan for pedestrian bridge

Ohio train derailment: Experts on toxic chemical risks

Virtual repurposing can help discover new uses for existing drugs

Takeaways from AdvaMed, the largest medical devices conference

Humana CEO Bruce Broussard to step down in 2024

STAT Readout: Today's biotech news includes Sana and Amylyx

hotspot

entertainment

Wikipedia

focus